Therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma – diagnostic and therapeutic dilemma

References

• Hemminki K, Försti A, Houlston R, et al. Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. Int J Cancer. 2021;149(12):1980–1996.
   PubMed Web of Science ®Google Scholar
• Blimark CH, Turesson I, Genell A, et al. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish myeloma registry. Haematologica. 2018;103(3):506–513.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770–1781.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after Stem-Cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–1791.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759–1769.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15(3):333–342.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Capelletti M, Park J, et al. Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. Leukemia. 2019;33(1):266–270.
   PubMed Web of Science ®Google Scholar
• Barnea Slonim L, Gao J, Burkart M, et al. Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome. Leukemia. 2021;35(7):2097–2101.
   PubMed Web of Science ®Google Scholar
• García-Muñoz R, Robles-de-Castro D, Muñoz-Rodríguez A, et al. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma. Leuk Lymphoma. 2013;54(12):2753–2755.
   PubMed Web of Science ®Google Scholar
• Tan M, Fong R, Lo M, et al. Lenalidomide and secondary acute lymphoblastic leukemia: a case series. Hematol Oncol. 2017;35(1):130–134.
   PubMed Web of Science ®Google Scholar
• Khan AM, Muzaffar J, Murthy H, et al. Acute lymphoblastic leukemia following lenalidomide maintenance for multiple myelome; two cases with unexpected presentation and good prognostic features. Case Rep Hematol. 2018;2018:1–5.
   Web of Science ®Google Scholar
• Junxun L, Junru L, Meilan C, et al. Three patients with multiple myeloma developing secondary lymphoblastic leukemia: case reports and review of the literature. Tumori 2016;102(Suppl 2):131–136.
   PubMed Web of Science ®Google Scholar
• Gonzalez MM, Kidd L, Quesada J, et al. Acute myelofibrosis and acute lymphoblastic leukemia in an elderly patient with previously treated multiple myeloma. Ann Clin Lab Sci. 2013;43(2):176–180.
   PubMed Web of Science ®Google Scholar
• Germans SK, Kulak O, Koduru P, et al. Lenalidomide-associated secondary B-lymphoblastic leukemia/lymphoma – a unique entity. Am J Clin Pathol. 2020;154(6):816–827.
   PubMed Web of Science ®Google Scholar
• Sinit RB, Hwang DG, Vishnu P, et al. B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review. BMC Cancer. 2019;19(1):1–9.
   PubMed Web of Science ®Google Scholar
• Sharma N, Hassoun H, Hatem J, et al. Cardiac ALL: Most unusual occurrence of lenalidomide-associated acute lymphoblastic leukemia with subsequent cardiac involvement. Cureus. 2019;11(10):e600–9.
   Web of Science ®Google Scholar
• Nair R, Gheith S, Popescu D, et al. A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide. Int J Clin Exp Pathol. 2014;7(5):2683–2689.
   PubMed Web of Science ®Google Scholar
• Tashakori M, Khoury JD. B acute lymphoblastic leukemia arising during maintenance therapy for multiple myeloma. Blood. 2020;136(23):2720.
   PubMed Web of Science ®Google Scholar
• Corre J, Munshi N, Avet-Loiseau H. Genetics of multiple myeloma: another heterogeneity level? Blood. 2015;125(12):1870–1876.
   PubMed Web of Science ®Google Scholar
• Mitchell JS, Li N, Weinhold N, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun. 2016;7:12050.
   PubMed Web of Science ®Google Scholar
• Østgård LSG, Medeiros BC, Sengeløv H, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33(31):3641–3649.
   PubMed Web of Science ®Google Scholar
• Saygin C, Kishtagari A, Cassaday RD, et al. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019;3(24):4228–4237.
   PubMed Web of Science ®Google Scholar
• Mahindra A, Raval G, Mehta P, et al. New cancers after autotransplantations for multiple myeloma. Biol Blood Marrow Transplant. 2015;21(4):738–745.
   PubMed Web of Science ®Google Scholar
• Thomas A, Mailankody S, Korde N, et al. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood. 2012;119(12):2731–2737.
   PubMed Web of Science ®Google Scholar
• Jones JR, Cairns DA, Gregory WM, et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the myeloma XI trial. Blood Cancer J. 2016;6(12):e506.
   PubMed Web of Science ®Google Scholar
• Musto P, Anderson KC, Attal M, et al. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2017;28(2):228–245.
   PubMed Web of Science ®Google Scholar
• Agostino NM, Ahmed B, Popescu D, et al. Transformation of the 5q- syndrome to acute lymphoblastic leukemia: a report of two cases and review of the literature. Int J Clin Exp Pathol. 2011;4(3):322–326.
   PubMed Web of Science ®Google Scholar
• Li J, Zhan J, Zhang FAN, et al. Secondary lymphoblastic leukemia occurring 38 months after the primary diagnosis of multiple myeloma: a case report. Oncol Lett. 2016;12(2):847–856.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Sexton R, Hoering A, et al. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. J Am Soc Hematol. 2012;120(8):1597–1600.
   Google Scholar
• Abdel Rahman ZH, Parrondo RD, Heckman MG, et al. Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia. Br J Haematol. 2022;196(4):963–966.
   PubMed Web of Science ®Google Scholar
• Moorman AV, Barretta E, Butler ER, et al. Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. Leukemia. 2022;36(3):625–636.
   PubMed Web of Science ®Google Scholar
• Safavi S, Paulsson K. Near-haploid and low-hypodiploid acute lymphoblastic leukemia: two distinct subtypes with consistently poor prognosis. Blood. 2017;129(4):420–423.
   PubMed Web of Science ®Google Scholar
• Chen Z, Sun Y, Xie W, et al. Is hyperdiploidy a favorable cytogenetics in adults with B-lymphoblastic leukemia? Cancer Med. 2019;8(9):4093–4099.
   PubMed Web of Science ®Google Scholar